Real-world evidence in cystic fibrosis modulator development: Establishing a path forward.
作者信息
Magaret Amalia, Warden Mark, Simon Noah, Heltshe Sonya, Mayer-Hamblett Nicole
机构信息
Departments of Biostatistics and Pediatrics, Seattle Children's Research Institute, University of Washington, Seattle, WA, USA.
Department of Epidemiology, Seattle Children's Research Institute, University of Washington, Seattle, WA, USA.
出版信息
J Cyst Fibros. 2020 May;19(3):e11-e12. doi: 10.1016/j.jcf.2020.03.020. Epub 2020 Apr 11.
Abstract
摘要
相似文献
1
Real-world evidence in cystic fibrosis modulator development: Establishing a path forward.
J Cyst Fibros. 2020 May;19(3):e11-e12. doi: 10.1016/j.jcf.2020.03.020. Epub 2020 Apr 11.
2
Important steps in the journey to highly effective CFTR modulator access for people with CF.
J Cyst Fibros. 2019 Sep;18(5):577-578. doi: 10.1016/j.jcf.2019.06.013.
3
Taskforce recommends coordinated effort to improve clinical research conduct and find highly effective CFTR-directed treatment for rare mutations.
J Cyst Fibros. 2019 Sep;18(5):579-580. doi: 10.1016/j.jcf.2019.06.014. Epub 2019 Jul 4.
4
Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery.
J Cyst Fibros. 2019 Sep;18(5):677-684. doi: 10.1016/j.jcf.2019.06.011. Epub 2019 Jul 11.
5
At the forefront of cystic fibrosis Basic Science research: 16th ECFS Basic Science Conference.
J Cyst Fibros. 2020 Mar;19(2):169-170. doi: 10.1016/j.jcf.2020.02.002. Epub 2020 Feb 14.
6
The impact of CFTR modulator therapies on CF airway microbiology.
J Cyst Fibros. 2020 May;19(3):359-364. doi: 10.1016/j.jcf.2019.07.008. Epub 2019 Aug 12.
7
A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
J Pediatr Health Care. 2019 May-Jun;33(3):356-364. doi: 10.1016/j.pedhc.2018.08.013.
8
Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders' consensus view.
J Cyst Fibros. 2020 Sep;19(5):688-695. doi: 10.1016/j.jcf.2020.05.012. Epub 2020 Jun 8.
9
Feasibility of placebo-controlled trial designs for new CFTR modulator evaluation.
J Cyst Fibros. 2017 Jul;16(4):496-498. doi: 10.1016/j.jcf.2017.02.012. Epub 2017 Mar 9.
10
The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial.
Ann Am Thorac Soc. 2018 Jan;15(1):1-2. doi: 10.1513/AnnalsATS.201708-668PS.
引用本文的文献
1
Statistical approaches for the integration of external controls in a cystic fibrosis clinical trial: a simulation and an application.
Am J Epidemiol. 2024 Dec 2;193(12):1796-1804. doi: 10.1093/aje/kwae148.
2
A new path for CF clinical trials through the use of historical controls.
J Cyst Fibros. 2022 Mar;21(2):293-299. doi: 10.1016/j.jcf.2021.11.007. Epub 2021 Dec 5.
3
Building global development strategies for cf therapeutics during a transitional cftr modulator era.
J Cyst Fibros. 2020 Sep;19(5):677-687. doi: 10.1016/j.jcf.2020.05.011. Epub 2020 Jun 7.
本文引用的文献
1
Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.
Am J Respir Crit Care Med. 2020 May 15;201(10):1193-1208. doi: 10.1164/rccm.201910-1943SO.
2
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
3
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
4
The future of cystic fibrosis care: a global perspective.
Lancet Respir Med. 2020 Jan;8(1):65-124. doi: 10.1016/S2213-2600(19)30337-6. Epub 2019 Sep 27.
5
Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery.
J Cyst Fibros. 2019 Sep;18(5):677-684. doi: 10.1016/j.jcf.2019.06.011. Epub 2019 Jul 11.
6
The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics.
J Diabetes Sci Technol. 2020 Mar;14(2):345-349. doi: 10.1177/1932296819832661. Epub 2019 Mar 12.
7
Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making.
Clin Pharmacol Ther. 2019 Apr;105(4):867-877. doi: 10.1002/cpt.1351. Epub 2019 Feb 25.
8
When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?
Clin Pharmacol Ther. 2017 Dec;102(6):924-933. doi: 10.1002/cpt.857. Epub 2017 Sep 25.
9
Feasibility of placebo-controlled trial designs for new CFTR modulator evaluation.
J Cyst Fibros. 2017 Jul;16(4):496-498. doi: 10.1016/j.jcf.2017.02.012. Epub 2017 Mar 9.
10
Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.
JAMA. 2014;311(4):368-77. doi: 10.1001/jama.2013.282034.
Zotero 插件